Castle Biosciences, Inc.
$25.16
▼
-0.84%
2026-04-21 06:16:00
castlebiosciences.com
NGM: CSTL
Explore Castle Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$744.77 M
Current Price
$25.16
52W High / Low
$44.28 / $14.59
Stock P/E
—
Book Value
$15.86
Dividend Yield
—
ROCE
-8.4%
ROE
-5.21%
Face Value
—
EPS
$-0.83
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
883
Beta
1.19
Debt / Equity
7.86
Current Ratio
5.26
Quick Ratio
5.11
Forward P/E
-42.54
Price / Sales
2.04
Enterprise Value
$425.19 M
EV / EBITDA
-208.53
EV / Revenue
1.24
Rating
Strong Buy
Target Price
$48.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | NeoGenomics, Inc. | $8.23 | — | $1.06 B | — | -6.93% | -12.43% | $13.74 / $4.72 | $6.49 |
| 2. | Illumina, Inc. | $131.09 | 24.09 | $19.95 B | — | 16.15% | 33.36% | $155.53 / $69.83 | $17.8 |
| 3. | IQVIA Holdings Inc. | $175.62 | 22.46 | $29.52 B | — | 10.59% | 21.44% | $247.05 / $134.65 | $38.34 |
| 4. | Danaher Corporation | $189.21 | 37.67 | $133.79 B | 0.82% | 6.12% | 7.05% | $242.8 / $180.03 | $74.32 |
| 5. | Qiagen N.V. | NOT FOUND | — | — | 0.64% | 9.02% | 11.57% | $57.81 / $38.8 | $18.33 |
| 6. | GRAIL, Inc. | $51.2 | — | $2.1 B | — | -18.79% | -16.07% | $118.84 / $25.56 | $63.92 |
| 7. | Agilent Technologies, Inc. | $122.3 | 26.99 | $34.7 B | 0.84% | 14.25% | 19.95% | $160.27 / $99.12 | $24.44 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 87.01 M | 83.04 M | 86.19 M | 87.99 M | 86.31 M | — |
| Operating Profit | -3.83 M | -6.8 M | -4.25 M | -27.93 M | 4.05 M | — |
| Net Profit | -2.33 M | -0.5 M | 4.52 M | -25.85 M | 9.59 M | — |
| EPS in Rs | -0.08 | -0.02 | 0.15 | -0.85 | 0.32 | 0.08 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 344.23 M | 332.07 M | 219.79 M | 137.04 M |
| Operating Profit | -42.81 M | 8.67 M | -67.98 M | -91.14 M |
| Net Profit | -24.16 M | 18.25 M | -57.47 M | -67.14 M |
| EPS in Rs | -0.8 | 0.6 | -1.9 | -2.22 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 578.56 M | 531.24 M | 453.34 M | 447.33 M |
| Total Liabilities | 107.68 M | 75.4 M | 62.07 M | 48.18 M |
| Equity | 470.87 M | 455.83 M | 391.27 M | 399.15 M |
| Current Assets | 361.1 M | 360.15 M | 295.63 M | 292.29 M |
| Current Liabilities | 68.68 M | 49.39 M | 47.67 M | 36.13 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 64.35 M | 64.87 M | -5.63 M | -41.66 M |
| Investing CF | -60.37 M | -50.14 M | -16.18 M | -166.54 M |
| Financing CF | -6.96 M | 6.14 M | -2.3 M | 1.51 M |
| Free CF | 28.33 M | 36.54 M | -19.25 M | -47.29 M |
| Capex | -36.02 M | -28.33 M | -13.62 M | -5.63 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 51.09% | 60.38% | — | — |
| Earnings Growth % | 131.75% | 14.41% | — | — |
| Profit Margin % | 5.49% | -26.15% | -48.99% | — |
| Operating Margin % | 2.61% | -30.93% | -66.51% | — |
| Gross Margin % | 81.87% | 79.53% | 76.64% | — |
| EBITDA Margin % | 11.48% | -20.49% | -42.57% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.